Posted on June 8th, 2010 by
In a Phase III clinical trial, the addition of the targeted therapy Avastin® (bevacizumab) to chemotherapy, followed by maintenance therapy with Avastin, slowed cancer progression among women with advanced ovarian, primary peritoneal, or Fallopian tube cancer. These results were presented at the 2010 annual meeting of the American Society of Clinical Oncology.
Ovarian cancer has the highest mortality rate of all gynecologic cancers. It is the fifth leading cause of cancer death among U.S. women, with an estimated 21,550 new cases and 14,600 deaths in 2009.
Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Outcomes for women diagnosed with advanced disease remain poor, and researchers continue to evaluate new approaches to treatment.
Avastin is a targeted therapy that blocks a protein known as VEGF. VEGF plays a key role in the development of new blood vessels. By blocking VEGF, Avastin deprives the cancer of nutrients and oxygen and inhibits its growth. Avastin has been approved for the treatment of selected patients with breast cancer, lung cancer, colorectal cancer, kidney cancer, or glioblastoma.
To evaluate the combination of Avastin and chemotherapy among women with ovarian cancer, researchers conducted a Phase III clinical trial among 1,873 women with newly diagnosed, advanced epithelial ovarian cancer, primary peritoneal cancer, or Fallopian tube cancer.
After surgery to remove as much of the cancer as possible, study participants were assigned to one of three treatment groups:
Chemotherapy consisted of carboplatin and paclitaxel.
Maintenance therapy refers to ongoing treatment after the initial treatment is completed.
These results suggest that Avastin slows cancer progression among women with advanced ovarian, primary peritoneal, or Fallopian tube cancer. The best outcomes were observed among women who received Avastin maintenance therapy after treatment with chemotherapy and Avastin.
Reference: Burger RA, Brady MF, Bookman MA et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or Fallopian tub cancer (FTC): A Gynecologic Oncology Group study. Presented at the 2010 annual meeting of the American Society of Clinical Oncology. June 4-8, 2010. Chicago, IL. Abstract LBA 1.
You must be logged-in to the site to post a comment.